CA1340716C - Inhibition de neoplasmes et de pathogenes eucaryotes stimulation; stimulation de fibroblastes et de lymphocytes a l'aide de peptides lytiques - Google Patents

Inhibition de neoplasmes et de pathogenes eucaryotes stimulation; stimulation de fibroblastes et de lymphocytes a l'aide de peptides lytiques

Info

Publication number
CA1340716C
CA1340716C CA000578682A CA578682A CA1340716C CA 1340716 C CA1340716 C CA 1340716C CA 000578682 A CA000578682 A CA 000578682A CA 578682 A CA578682 A CA 578682A CA 1340716 C CA1340716 C CA 1340716C
Authority
CA
Canada
Prior art keywords
lytic peptide
selectively
peptide
medicament
selectively lytic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000578682A
Other languages
English (en)
Inventor
Jesse M. Jaynes
Frederick M. Enright
Kenneth L. White
Gale Jeffers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helix Biomedix Inc
Original Assignee
Helix Biomedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Biomedix Inc filed Critical Helix Biomedix Inc
Application granted granted Critical
Publication of CA1340716C publication Critical patent/CA1340716C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA000578682A 1987-09-29 1988-09-28 Inhibition de neoplasmes et de pathogenes eucaryotes stimulation; stimulation de fibroblastes et de lymphocytes a l'aide de peptides lytiques Expired - Fee Related CA1340716C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10217587A 1987-09-29 1987-09-29
US102,175 1987-09-29

Publications (1)

Publication Number Publication Date
CA1340716C true CA1340716C (fr) 1999-08-24

Family

ID=33434388

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000578682A Expired - Fee Related CA1340716C (fr) 1987-09-29 1988-09-28 Inhibition de neoplasmes et de pathogenes eucaryotes stimulation; stimulation de fibroblastes et de lymphocytes a l'aide de peptides lytiques

Country Status (1)

Country Link
CA (1) CA1340716C (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117487750A (zh) * 2023-11-08 2024-02-02 青岛西凯生物技术有限公司 Nk细胞在制备治疗免疫相关病症的药物中的用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117487750A (zh) * 2023-11-08 2024-02-02 青岛西凯生物技术有限公司 Nk细胞在制备治疗免疫相关病症的药物中的用途
CN117487750B (zh) * 2023-11-08 2024-06-21 青岛西凯生物技术有限公司 Nk细胞在制备治疗免疫相关病症的药物中的用途

Similar Documents

Publication Publication Date Title
US5962410A (en) Inhibition of eucaryotic pathogens with lytic peptides
EP1004595B1 (fr) Peptides lytiques et prolifératifs et leur emploi comme agents pharmaceutiques et phytopharmaceutiques
US6255282B1 (en) Lytic peptides
EP0335423B1 (fr) G-CSF humain modifié
EP0365598B1 (fr) Polypeptides antimicrobiens therapeutiques, leur utilisation et procedes de preparation
Kang et al. Structure–biological activity relationships of 11‐residue highly basic peptide segment of bovine lactoferrin
US6288212B1 (en) Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
AU689487B2 (en) Protegrins
KR20140039157A (ko) 항미생물성 융합 화합물 및 그의 용도
DE60021188T2 (de) Modifizierter humaner granulozyten-kolonie stimulierenderfaktor sowie verfahren zur herstellung desselben
DE69823501T2 (de) Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin-abhängiger krankheiten
US7262163B2 (en) Short amphipathic peptides with activity against bacteria and intracellular pathogens
US9593151B2 (en) Use of fusion protein
CN115536737A (zh) 眼镜王蛇抗菌肽oh-cath30在抗水产动物致病菌中的应用
CA1340716C (fr) Inhibition de neoplasmes et de pathogenes eucaryotes stimulation; stimulation de fibroblastes et de lymphocytes a l'aide de peptides lytiques
JP2005120050A (ja) 新規抗菌性ペプチドとその利用
CN111944060B (zh) 一种兼具抗菌、抗炎、解毒活性的多功能杂合肽及其应用
CN109867710B (zh) 一种新型广谱抗菌肽samp1-a3及其制备方法
Son et al. Effects of C-terminal residues of 12-mer peptides on antibacterial efficacy and mechanism
JP4154218B2 (ja) 新規抗菌性ポリペプチドとその利用
JPH0730120B2 (ja) 抗バクテリア・抗マラリア性ペプタイド
CN116903753B (zh) 一种广谱抗原虫多肽及其制备与应用
JPS61205497A (ja) インタ−ロイキン−２の製造方法
JP5218843B2 (ja) 抗菌ペプチド及びその利用
CN115925863A (zh) 暗纹东方鲀抗菌肽ToNK-lysin及其应用

Legal Events

Date Code Title Description
MKLA Lapsed

Effective date: 20140825